WST

West Pharmaceutical Services Inc

Add to Watchlist

Advanced Chart

257.760

-5.75(-2.182%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

262.7097

Open

261.030

VWAP

Vol

1.32M

Mkt Cap

18.53B

Low

256.670

Amount

EV/EBITDA(TTM)

23.96

Total Shares

72.84M

18.65B

EV/OCF(TTM)

27.55

P/S(TTM)

6.50

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

752.92M

+7.87%

1.602

+10.45%

796.60M

+6.38%

1.781

-2.14%

788.20M

+5.53%

1.684

-8.95%

Estimates Revision

The market is revising Downward the revenue expectations for West Pharmaceutical Services, Inc. (WST) for FY2025, with the revenue forecasts being adjusted by -0.07% over the past three months. During the same period, the stock price has changed by 19.27%.

Revenue Estimates for FY2025

Revise Downward

-0.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.18%

In Past 3 Month

Stock Price

Go Up

+19.27%

In Past 3 Month

8 Analyst Rating

7.24% Upside

Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 276.43 USD with a low forecast of 245.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

7.24% Upside

Current: 257.760

Low

245.00

Averages

276.43

High

325.00

7.24% Upside

Current: 257.760

Low

245.00

Averages

276.43

High

325.00

UBS

Buy

maintain

$285 -> $320

2025-07-25

New

Reason

UBS

Price Target

$285 -> $320

2025-07-25

New

maintain

Buy

Reason

UBS raised the firm's price target on West Pharmaceutical to $320 from $285 and keeps a Buy rating on the shares. Growth is getting back on track for West Pharmaceutical, the analyst tells investors in a research note.

Evercore ISI

Outperform

upgrade

$275 -> $350

2025-07-24

New

Reason

Evercore ISI

Price Target

$275 -> $350

2025-07-24

New

upgrade

Outperform

Reason

Evercore ISI raised the firm's price target on West Pharmaceutical to $350 from $275 and keeps an Outperform rating on the shares following quarterly results. The firm says the company is delivering across the board amid a choppy macro environment, and setting the table for a strong second half of the year and 2026.

Barclays

Luke Sergott

Equal Weight

initiated

$245

2025-06-24

Reason

Barclays

Luke Sergott

Price Target

$245

2025-06-24

initiated

Equal Weight

Reason

Barclays analyst Luke Sergott initiated coverage of West Pharmaceutical with an Equal Weight rating and $245 price target. The company has a strong market position in its core High-Value Products unit, but in recent quarters, it has been plagued by issues in much smaller, non-core businesses, notably SmartDose and continuous glucose monitoring manufacturing, the analyst tells investors in a research note. The firm says the biggest concern for the business is oral GLP-1s coming to market.

Citi

Buy

maintain

$300

2025-05-22

Reason

Citi

Price Target

$300

2025-05-22

maintain

Buy

Reason

Evercore ISI Group

Daniel Markowitz

Buy

Initiates

$275

2025-03-18

Reason

Evercore ISI Group

Daniel Markowitz

Price Target

$275

2025-03-18

Initiates

Buy

Reason

Evercore ISI initiated coverage of West Pharmaceutical with an Outperform rating and $275 price target. The bull thesis on the stock is tied to mix shift in high value components which primarily serves the biologics market where West Pharmaceutical has a roughly 90% participation rate, the analyst tells investors in a research note. Fundamentals in the biologics market are strong, enabling significant margin accretion, the firm added.

Keybanc

Paul Knight

Buy

Maintains

$470 → $325

2025-02-14

Reason

Keybanc

Paul Knight

Price Target

$470 → $325

2025-02-14

Maintains

Buy

Reason

KeyBanc analyst Paul Knight lowered the firm's price target on West Pharmaceutical to $325 from $470 to reflect lower FY25 estimates and confidence in long-term fundamentals, while keeping an Overweight rating on the shares. The firm notes West beat Q4 expectations, but the stock is down significantly due to disappointing FY25 guidance of 2%-3% organic growth vs. KeyBanc at +7.2% and the Street at 6.1%.

See All Ratings

Valuation Metrics

The current forward P/E ratio for West Pharmaceutical Services Inc (WST.N) is 41.05, compared to its 5-year average forward P/E of 44.43. For a more detailed relative valuation and DCF analysis to assess West Pharmaceutical Services Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

44.43

Current PE

41.05

Overvalued PE

52.97

Undervalued PE

35.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

28.88

Current EV/EBITDA

26.80

Overvalued EV/EBITDA

33.85

Undervalued EV/EBITDA

23.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

8.27

Current PS

6.64

Overvalued PS

9.78

Undervalued PS

6.76

Financials

Annual

Quarterly

FY2025Q2

YoY :

+9.17%

766.50M

Total Revenue

FY2025Q2

YoY :

+22.80%

157.80M

Operating Profit

FY2025Q2

YoY :

+18.73%

126.80M

Net Income after Tax

FY2025Q2

YoY :

+20.53%

1.82

EPS - Diluted

FY2025Q2

YoY :

+57.25%

101.90M

Free Cash Flow

FY2025Q2

YoY :

+9.07%

35.73

Gross Profit Margin - %

FY2025Q2

YoY :

-6.37%

11.62

FCF Margin - %

FY2025Q2

YoY :

+8.52%

17.20

Net Margin - %

FY2025Q2

YoY :

-10.92%

16.48

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

526.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 196.32% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

12.8K

Volume

6-9

Months

450.0K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.4M

Volume

Months

6-9

484.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

24.0K

USD

6-9

Months

8.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

8.0K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

526.9K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

WST News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

12:00:52

West Pharmaceutical rises 22.2%

2025-07-24

10:00:03

West Pharmaceutical rises 23.9%

2025-07-24

09:55:01

Early notable gainers among liquid option names on July 24th

News

8.0

12:00 PMNASDAQ.COM

Ex-Dividend Reminder: Constellation Brands, Conagra Brands and West Pharmaceutical Services

2.0

07-27Benzinga

Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio?

4.5

07-24NASDAQ.COM

S&P 500 and Nasdaq 100 Post Record Highs on Tech Stock Strength

People Also Watch

TKO

TKO Group Holdings Inc

Koninklijke Philips NV

25.660

USD

-1.91%

FAQ

What is West Pharmaceutical Services Inc (WST) stock price today?

The current price of WST is 257.76 USD — it has decreased -2.18 % in the last trading day.

WST

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

WST News & Events

Events Timeline

News

People Also Watch

FAQ

What is West Pharmaceutical Services Inc (WST) stock price today?

What is West Pharmaceutical Services Inc (WST)'s business?

What is the price predicton of WST Stock?

What is West Pharmaceutical Services Inc (WST)'s revenue for the last quarter?

What is West Pharmaceutical Services Inc (WST)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for West Pharmaceutical Services Inc (WST)'s fundamentals?

How many employees does West Pharmaceutical Services Inc (WST). have?

What is West Pharmaceutical Services Inc (WST) market cap?